The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Open accessAbstract
BACKGROUND: Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features have made it an obvious target for intraperitoneal (IP) chemotherapy. Chemotherapy for ovarian cancer is usually given as an intravenous (IV) infusion repeatedly over five to eight cycles. Intraperitoneal chemotherapy is given by infusion of the chemotherapeutic agent directly into the peritoneal cavity. There are biological reasons why this might increase the anticancer effect and reduce some systemic adverse effects in comparison to IV therapy. OBJECTIVES: To determine if adding a component of the chemotherapy regime into the peritoneal cavity affects overall survival, progression-free survival, quality of life (QOL) and toxicity in the primary treatment of epithelial ovarian cancer. SEARCH METHODS: We searched the Gynaecological Cancer Review Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2011, MEDLINE (1951 to May 2011) and EMBASE (1974 to May 2011). We updated these searches in February 2007, August 2010, May 2011 and September 2015. In addition, we handsearched and cascade searched the major gynaecological oncology journals up to May 2011. SELECTION CRITERIA: The analysis was restricted to randomised controlled trials (RCTs) assessing women with a new diagnosis of primary epithelial ovarian cancer, of any FIGO stage, following primary cytoreductive surgery. Standard IV chemotherapy was compared with chemotherapy that included a component of IP administration. DATA COLLECTION AND ANALYSIS: We extracted data on overall survival, disease-free survival, adverse events and QOL and performed meta-analyses of hazard ratios (HR) for time-to-event variables and relative risks (RR) for dichotomous outcomes using RevMan software. MAIN RESULTS: Nine randomised trials studied 2119 women receiving primary treatment for ovarian cancer. We considered six trials to be of high quality. Women were less likely to die if they received an IP component to chemotherapy (eight studies, 2026 women; HR = 0.81; 95% confidence interval (CI): 0.72 to 0.90). Intraperitoneal component chemotherapy prolonged the disease-free interval (five studies, 1311 women; HR = 0.78; 95% CI: 0.70 to 0.86). There was greater serious toxicity with regard to gastrointestinal effects, pain, fever and infection but less ototoxicity with the IP than the IV route. AUTHORS' CONCLUSIONS: Intraperitoneal chemotherapy increases overall survival and progression-free survival from advanced ovarian cancer. The results of this meta-analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of the decision making process. However, the potential for catheter related complications and toxicity needs to be considered when deciding on the most appropriate treatment for each individual woman. The optimal dose, timing and mechanism of administration cannot be addressed from this meta-analysis. This needs to be addressed in the next phase of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Intraperitoneal Cisplatin with Systemic Thiosulfate Protection
HOWELL, S. B., PFEIFLE, C. L., WUNG, W. E., OLSHEN, R. A., LUCAS, W. E., YON, J. L., & GREEN, M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-6-845 · Cited by 485
Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer
Burghardt, E., Girardi, F., Lahousen, M., Tamussino, K., & Stettner, H. (1991) · Gynecologic Oncology · doi:10.1016/0090-8258(91)90099-q · Cited by 285
Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., & Cella, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3494 · Cited by 197
USE OF NITROGEN MUSTARD IN TREATMENT OF SEROUS EFFUSIONS OF NEOPLASTIC ORIGIN
Weisberger, A. S., Levine, B., & Storaasli, J. P. (1955) · Journal of the American Medical Association · doi:10.1001/jama.1955.02960350004002 · Cited by 182
D, M. D. M., Kusamura, S., Virzì, S., Puccio, F., Macrì, A., Famulari, C., Solazzo, M., Bonomi, S., Iusco, D. R., & Baratti, D. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.004 · Cited by 149
Gadducci, A., Carnino, F., Chiara, S., Brunetti, I. M., Tanganelli, L., Romanini, A., Bruzzone, M., & Conte, P. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5677 · Cited by 140
Lambert, H. E., Rustin, G. J. S., Gregory, W. M., & Nelstrop, A. E. (1997) · Annals of Oncology · doi:10.1023/a:1008256431090 · Cited by 119
Piccart, M. J., Floquet, A., Scarfone, G., Willemse, P. H. B., Emerich, J., Vergote, I. B., Giurgea, L., Coens, C., Awada, A. H., & Vermorken, J. B. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13360.x · Cited by 119
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., & Johnson, N. P. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub2 · Cited by 86
Self-citationFujiwara, K., Nagao, S., Kigawa, J., Noma, J., Akamatsu, N., Miyagi, Y., Numa, F., Okada, M., & Aotani, E. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a29dfe · Cited by 28
MacKay, H. J., Provencheur, D., Heywood, M. S., Tu, D., Eisenhauer, E. A., Oza, A. M., & Meyer, R. M. (2011) · Current Oncology · doi:10.3747/co.v18i2.725 · Cited by 27
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
Gray, H. J., Shah, C., Swensen, R. E., Tamimi, H. K., & Goff, B. A. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.054 · Cited by 19
Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
Fujiwara, K. (2012) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2012.23.2.75 · Cited by 19
Cited by
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Metadata
- Authors
- Jaaback, K., Johnson, N., & Lawrie, T. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-01-12
- Volume
- 2016
- Issue
- 1
- Pages
- CD005340-CD005340
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1902157971
- Cited by
- 359
- References
- 24
- FWCI
- 38.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.